Relievant Medsystems Announces Publication of New INTRACEPT Trial Data Demonstrating Long-Term Relief for Chronic Low Back Pain 24 Months Post-Procedure

NEXT STORY
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
PREV STORY
23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

author_avatar
NASDAQ Market News

Intercept Announces Ocaliva® (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting

NEW YORK, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a ...

author_avatar
NASDAQ Market News

ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference

author_avatar
NASDAQ Market News